The Oxford Science Park

Find Out The Latest

Keep in touch with news and developments from The Oxford Science Park and its occupiers here.

You can also follow us on LinkedIn

Oxford Vacmedix announce successful Phase 1 trial results for cancer

23 Apr 2026

Oxford Vacmedix , a biotech company developing novel immunotherapies to treat cancer, has announced the successful completion of the Phase 1 trial of OVM-200. The primary endpoint for safety has been met as well as the secondary endpoints for immune response and dose selection. In addition, there are early observations of clinical efficacy in NSCLC and in prostate cancer. This Phase 1 clinical trial of OVM-200 is a multicentre, open‑label,... Read more

Vivid Dx: an Oxford spinout racing the clock on sepsis

20 Apr 2026

In the fight against sepsis, speed is everything. Every hour without the right diagnosis increases the risk of death, yet in hospitals around the world, clinicians are still forced to wait days for answers. That stark reality is what drives Vivid Dx, a diagnostics company based at The Oxford Science Park that is transforming how bloodstream infections are detected and treated. The company is built on world-class University of Oxford research,... Read more

Wireless innovator CableFree celebrates 30 years at The Oxford Science Park

31 Mar 2026

CableFree marked a major milestone recently as it celebrated its 30th anniversary. Since its founding in 1996, CableFree has been based at The Oxford Science Park, where it has grown from a small team of visionary engineers into a global provider of 4G, 5G, microwave, millimetre‑wave and Free Space Optics solutions installed in over 90 countries. Over three decades, the company has powered networks across industries including telecoms,... Read more

Evox Therapeutics enters partnership to evaluate new gene editing technology for Rett Syndrome

27 Feb 2026

Evox Therapeutics, a biotechnology company developing innovative therapies for genetically driven neurodegenerative diseases using a next-generation gene editing modality, has announced it is initiating a collaboration with the Rett Syndrome Research Trust (RSRT) to assess the feasibility of using the company’s ExoEdit® exosome-based delivery platform to enable the development of a gene editing treatment for Rett syndrome. Rett syndrome is a... Read more

Boehringer Ingelheim licenses novel oral therapeutics program from Sitryx Therapeutics